> News > AC BioScience appoints Peter Hug, Ph.D., to the Board of Directors
AC BioScience appoints Peter Hug, Ph.D., to the Board of Directors
Lausanne, Switzerland, February 1, 2022 - AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies, announced today that Peter Hug, Ph.D., has been appointed as a new member of its Board of Directors. Dr. Hug is a former Senior Executive of Roche.
Andreas Schläpfer, Chairman of the Board and Co-founder of AC BioScience, said: “We are delighted to welcome Peter to our Board. Peter’s network, long history and experience of pharma partnering and global commercial development will significantly strengthen our efforts in opening business opportunities through the licensing of our products to the pharma industry”.
Dr. Hug is a 35-year veteran of F. Hoffmann-La Roche Ltd. until his retirement in 2018. After having served as Executive Vice President of Roche Pharma Partnering with global responsibilities for licensing, strategic alliances and mergers and acquisitions, he became Head of Pharma Region Europe and afterwards Head of the Pharma Division of EEMEA Region (Eastern Europe, Middle East, Africa). Dr. Hug brings extensive pharmaceutical experience, notably in the development and management of strategic opportunities, the formation of corporate alliances and bringing therapeutic products to market.
Dr. Hug said: “I am excited to join and work with the Board of Directors of AC BioScience at this inflection point when the company starts to prepare for strategic partnerships for its products under clinical validation.”